{
    "organizations": [],
    "uuid": "c30c550d65a0446ec68d67deb5c0b19d2ecc5a12",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-onconova-therapeutics-announces-li/brief-onconova-therapeutics-announces-license-agreement-with-pint-pharma-to-commercialize-rigosertib-idUSFWN1QN0HL",
    "ord_in_thread": 0,
    "title": "BRIEF-Onconova Therapeutics Announces License Agreement With Pint Pharma To Commercialize Rigosertib",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 5 (Reuters) - Onconova Therapeutics Inc:\n* ONCONOVA THERAPEUTICS ANNOUNCES LICENSE AGREEMENT WITH PINT PHARMA TO COMMERCIALIZE RIGOSERTIB FOR TREATMENT OF MYELODYSPLASTIC SYNDROMES IN LATIN AMERICA\n* ONCONOVA THERAPEUTICS INC - ONCONOVA ALSO ELIGIBLE TO RECEIVE UP TO $42.75 MILLION IN REGULATORY AND SALES MILESTONES\n* ONCONOVA THERAPEUTICS - IN EXCHANGE FOR RIGHTS, PINT WILL MAKE INVESTMENT TOTALING UP TO $2.5 MILLION BY PURCHASING SHARES AT A PREMIUM TO MARKET\n* ONCONOVA THERAPEUTICS INC - RIGOSERTIB TOP-LINE DATA EXPECTED IN 2019 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-03-05T21:11:00.000+02:00",
    "crawled": "2018-03-06T22:36:40.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "onconova",
        "therapeutic",
        "inc",
        "onconova",
        "therapeutic",
        "announces",
        "license",
        "agreement",
        "pint",
        "pharma",
        "commercialize",
        "rigosertib",
        "treatment",
        "myelodysplastic",
        "syndrome",
        "latin",
        "america",
        "onconova",
        "therapeutic",
        "inc",
        "onconova",
        "also",
        "eligible",
        "receive",
        "million",
        "regulatory",
        "sale",
        "milestone",
        "onconova",
        "therapeutic",
        "exchange",
        "right",
        "pint",
        "make",
        "investment",
        "totaling",
        "million",
        "purchasing",
        "share",
        "premium",
        "market",
        "onconova",
        "therapeutic",
        "inc",
        "rigosertib",
        "data",
        "expected",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}